NetScientific plc

Equities

NSCI

GB00BN4R5Q82

Investment Management & Fund Operators

Market Closed - London S.E. Other stock markets 11:35:12 2024-04-26 am EDT			5-day change	1st Jan Change
63 ^GBX	0.00%		0.00%	+5.00%

Apr. 15	Netscientific's ProAxsis Secures Investment for Product Development	MT
Apr. 15	NetScientific investee secures funding to develop product range	AN

NetScientific's portfolio company updates on cancer trial

November 09, 2023 at 02:42 pm EST

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor -

Portfolio company, PDS Biotechnology Corp, announces updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor in two groups of advanced cancer patients with various types of human papillomavirus 16-positive cancers. Says 75% of immune checkpoint inhibitor naïve patients remain alive at 36 months. In the ICI resistant group, the 12-month OS rate was 72% and the triple combination achieved a median OS of approximately 20 months.

Current stock price: 57.50p

12-month change: down 4%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
PDS LIMITED	481 INR	+1.06%	+4.16%	762M
NETSCIENTIFIC PLC	63 GBX	0.00%	0.00%	18.79M
PDS BIOTECHNOLOGY CORPORATION	3.27 USD	+0.31%	+23.63%	120M

Latest news about NetScientific plc

Netscientific's ProAxsis Secures Investment for Product Development	Apr. 15	MT
NetScientific investee secures funding to develop product range	Apr. 15	AN
Empire Metals targets key milestones in Australia	Mar. 27	AN
NetScientific "significantly" advances strategic goals	Mar. 13	AN
Esken's Southend Airport faces further allegations	Jan. 23	AN
Netscientific's Glycotest Receives $1 Million Investment from Fosun	Jan. 23	MT
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd.	Jan. 22	CI
NetScientific's DeepTech Recycling Closes GBP1 Million Fundraising	Dec. 01	MT
NetScientific investee DeepTech Recycling bags GBP1 million	Dec. 01	AN
NetScientific's portfolio company updates on cancer trial	Nov. 09	AN
Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	Nov. 09	CI
NetScientific's EMV Leads Investment Round in Portfolio Company Ventive	Nov. 06	MT
NetScientific investee claims promising results in biomarker study	23-10-23	AN
NetScientific portfolio company updates on cancer trial	23-10-03	AN
EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens	23-09-28	AN
Earnings Flash (NSCI.L) NETSCIENTIFIC Posts H1 Revenue GBP770,000	23-09-28	MT
NetScientific plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
NetScientific's Q-Bot completes GBP3.5 million investment programme	23-09-13	AN
NetScientific's PDS suffers wider loss as R&D costs mount	23-08-14	AN
Pendragon quarterly trading momentum maintained	23-06-30	AN
DName-iT NV announced that it has received Â£0.5 million in funding from NetScientific plc, EMV Capital Ltd, KBC Group NV, BNP Paribas Fortis SA and other investors	23-06-29	CI
TinyBuild bemoans disappointing interim performance	23-06-29	AN
NetScientific investee Vortex nabs six-figure investment	23-06-22	AN
NetScientific Portfolio Company Completes GBP3 Million Investment Round	23-06-22	MT
FTSE 100 Hits Two-Month Low as Chinese Economy Raises Concerns	23-05-31	DJ

Chart NetScientific plc

Duration

Period

More charts

Company Profile

NetScientific plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of innovative companies. The Company identifies, invests in, and builds high growth companies in the United Kingdom and internationally. It employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Limited. The Company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. Its portfolio consists of a combination of direct investments and capital under advisory (CUA). The Company has about 24 portfolio companies with a focus on life sciences, technology, and sustainability. The Company's subsidiaries include EMV Capital Limited, Glycotest, Inc., and ProAxsis Limited, among others.

Sector

Investment Management & Fund Operators

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Venture Capital

	1st Jan change	Capi.
NETSCIENTIFIC PLC	+5.00%	18.79M
UMBRA COMPANIES INC.	+31.41%	12.02B
HERCULES CAPITAL, INC.	+14.40%	3.06B
HBM HEALTHCARE INVESTMENTS AG	+2.96%	1.42B
CION INVESTMENT CORPORATION	+1.15%	616M
VERUSA HOLDING	+35.79%	577M
MOLTEN VENTURES PLC	-10.84%	579M
OCTOPUS APOLLO VCT PLC	-4.17%	492M
WOORI TECHNOLOGY INVESTMENT CO., LTD	+33.85%	488M
BRITISH SMALLER COMPANIES VCT PLC	+3.90%	304M

Venture Capital